Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor Management.

Cells - 29 Dec 2025

Yaacov Adar, Gillis Roni, Salim Jaber, Katz Daniela, Asna Noam, Paldor Iddo, Grinshpun Albert

Abstract excerpt

Temozolomide (TMZ) remains foundational in the management of adult-type diffuse gliomas in general, and glioblastoma specifically. However, its efficacy harbors an evolutionary trade-off. TMZ drives its cytotoxicity through generating O6-methylguanine lesions, especially active in MGMT-silenced, mismatch repair (MMR)-proficient tumors. By selecting for acquired MMR-deficient subclones, often via MSH6...

Topics

Join the communities discussing this publication.

Antineoplastic Agents, Alkylating
Brain Neoplasms
Drug Resistance, Neoplasm
ATR gene
AURKA gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 41511341
DOI: 10.3390/cells15010057
PMCID: PMC12786236

Genes

ATR
AURKA
MGMT
MSH6
WEE1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor Management.PMID 41511341Read ↗

Mechanisms and therapeutic implications of hypermutation in gliomas.Semantic proximity Read ↗

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferaseSemantic proximity Read ↗

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive reviewSemantic proximity Read ↗

Temozolomide-associated hypermutation in gliomas.Semantic proximity Read ↗

Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in GlioblastomaSemantic proximity Read ↗

The Role of Molecular Diagnostics in the Management of Patients with Gliomas.Semantic proximity Read ↗

MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.Semantic proximity Read ↗

Mechanisms of Resistance to Current Glioblastoma TherapiesSemantic proximity Read ↗

Therapeutic Targets in Diffuse Midline Gliomas—An Emerging LandscapeSemantic proximity Read ↗

One size should not fit all: advancing toward personalized glioblastoma therapy.Semantic proximity Read ↗

The Amazing and Deadly Glioma Race.Semantic proximity Read ↗

MYC amplification at diagnosis drives therapy-induced hypermutation of recurrent gliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.